Nama's AI scorecard currently rates Abbott Laboratories Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ABT's P/E ratio?

Abbott Laboratories trades at a trailing price-to-earnings ratio of 20.4.

When does ABT report earnings?

Abbott Laboratories's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $1.64.

What is the ABT price target?

The median analyst price target from 26 analysts is $120.00, with a range of $100.00 – $130.00.

Is ABT Shariah compliant?

Nama's AAOIFI-style screen reads Abbott Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does ABT pay a dividend?

Yes — Abbott Laboratories's dividend yield is 2.3%.

Nama Insights

Abbott Laboratories (ABT)

Healthcare · Medical Devices · NYSE

S&P 500

Abbott Laboratories (ABT) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $190.39B, a trailing price-to-earnings ratio of 20.4 and a free-cash-flow yield of 3.9%. Over the most recent reported fiscal year, revenue grew 5.7% and free cash flow per share grew 16.4%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -21.0% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-22.9%

How far the last close sits under the highest price of the past five years.

Market cap	$190.39B
Trailing P/E	20.4
Price / book	3.7
Price / sales	3.9
FCF yield	3.9%
Dividend yield	2.3%
Gross margin	56.3%
Operating margin	17.1%
Net margin	13.9%
Revenue growth (YoY)	+5.7%
Revenue growth (3-yr annual)	+0.5%
EPS growth (YoY)	+10.3%
FCF/share growth (YoY)	+16.4%
Beta	0.6
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

ABT earnings

Next report: Jan 28, 2027 (Q4 2026, EPS estimate $1.64). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 21, 2026	$1.42	$1.42	+0.0%	$13.01B
Q2 2026	Jul 16, 2026	$1.31	$1.28	+2.3%	—
Q1 2026	Apr 16, 2026	$1.15	$1.15	+0.0%	$11.16B
Q4 2025	Jan 22, 2026	$1.50	$1.49	+0.7%	$11.46B

ABT analyst price target

Median target $120.00 from 26 analysts, ranging $100.00 – $130.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7
STE	STERIS	$24.60B	23.2

Explore live ABT data on Nama Insights →

Recent Congressional trades

Abbott Laboratories trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas H. Kean	House	Sell	$1,001 - $15,000	Oct 30, 2026
Pete Sessions	House	Sell	$50,001 - $100,000	Oct 27, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Richard W. Allen	House	Sell	$15,001 - $50,000	Aug 18, 2026
Richard Dean McCormick	House	Sell	$1,001 - $15,000	Aug 14, 2026
Mike Kelly	House	Sell	$1,001 - $15,000	Aug 12, 2026
Alan Armstrong	Senate	Sell	$15,001 - $50,000	Jul 21, 2026
Rick Larsen	House	Sell	$1,001 - $15,000	Jul 12, 2026
Richard Dean McCormick	House	Buy	$1,001 - $15,000	Jul 9, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jul 2, 2026
Julie Johnson	House	Sell	$1,001 - $15,000	Jun 12, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Jun 8, 2026

ABT FAQ

Is ABT a buy?: Nama's AI scorecard currently rates Abbott Laboratories Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ABT's P/E ratio?: Abbott Laboratories trades at a trailing price-to-earnings ratio of 20.4.
When does ABT report earnings?: Abbott Laboratories's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $1.64.
What is the ABT price target?: The median analyst price target from 26 analysts is $120.00, with a range of $100.00 – $130.00.
Is ABT Shariah compliant?: Nama's AAOIFI-style screen reads Abbott Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does ABT pay a dividend?: Yes — Abbott Laboratories's dividend yield is 2.3%.